MARKET

INFI

INFI

Infinity Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7500
+0.1469
+24.36%
After Hours: 0.7600 +0.01 +1.33% 19:22 05/27 EDT
OPEN
0.6061
PREV CLOSE
0.6031
HIGH
0.7500
LOW
0.5801
VOLUME
1.32M
TURNOVER
0
52 WEEK HIGH
3.890
52 WEEK LOW
0.4605
MARKET CAP
66.87M
P/E (TTM)
-1.4476
1D
5D
1M
3M
1Y
5Y
BRIEF-Infinity Pharmaceuticals - On May 24, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
reuters.com · 4d ago
Infinity Pharmaceuticals Gets Nasdaq Warning for Lack of Compliance With Minimum Bid Price Rule
MT Newswires · 4d ago
CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space
Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech
Seekingalpha · 5d ago
Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating
MT Newswires · 5d ago
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 05/19 17:16
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will ...
Business Wire · 05/17 12:35
Infinity Pharmaceuticals's Return On Capital Employed Insights
Benzinga Pro data, Infinity Pharmaceuticals (NASDAQ:INFI) reported Q1 sales of $652.00 thousand. Earnings fell to a loss of $12.44 million, resulting in a 6.74% decrease from last quarter.
Benzinga · 05/13 13:56
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:45
More
No Data
Learn about the latest financial forecast of INFI. Analyze the recent business situations of Infinity Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
85.71%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average INFI stock price target is 6.07 with a high estimate of 11.00 and a low estimate of 3.000.
High11.00
Average6.07
Low3.000
Current 0.7500
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 119
Institutional Holdings: 42.54M
% Owned: 47.71%
Shares Outstanding: 89.16M
TypeInstitutionsShares
Increased
29
2.66M
New
10
4.73M
Decreased
32
10.32M
Sold Out
18
1.75M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Adelene Perkins
President/Treasurer
Lawrence Bloch
Senior Vice President/General Counsel/Secretary
Seth Tasker
Chief Scientific Officer
Stephane Peluso
Other
Robert Ilaria
Lead Director/Independent Director
Norman Selby
Director
Samuel Agresta
Director
Brian Schwartz
Independent Director
David Beier
Independent Director
Anthony Evnin
Independent Director
Richard Gaynor
Independent Director
Sujay Kango
No Data
No Data
About INFI
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.

Webull offers kinds of Infinity Pharmaceuticals Inc. stock information, including NASDAQ:INFI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INFI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INFI stock methods without spending real money on the virtual paper trading platform.